Search research articles
Contact Us
Filters
Showing results (31-40 of 46) with videos related to
Page
of 5
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
July 30, 2010
A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit: unplanned admissions as an early indicator of patient attrition
Andre T Brunetto, Joo Ern Ang, David Olmos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 20, 2007
Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers
Ruth Plummer, Gerhardt Attard, Simon Pacey, et al.
The Lancet. Oncology
|
February 2, 2015
Outcomes and endpoints in cancer trials: bridging the divide
Michelle K Wilson, Deborah Collyar, Diana T Chingos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 24, 2011
Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer
Jonathan A Ledermann, Allan Hackshaw, Stan Kaye, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 18, 2008
Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors
Johann S de Bono, Rebecca Kristeleit, Anthony Tolcher, et al.
Cancer
|
October 8, 2016
A study of motivations and expectations of patients seen in phase 1 oncology clinics
Saoirse O Dolly, Eleftheria Kalaitzaki, Martina Puglisi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 12, 2017
Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors
Malaka Ameratunga, Maxime Chénard-Poirier, Irene Moreno Candilejo, et al.
The Journal of Pathology
|
November 21, 2012
Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor
Louise J Barber, Shahneen Sandhu, Lina Chen, et al.
Cancer Discovery
|
March 1, 2017
Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline <i>BRCA1/2</i> Mutations and Selected Sporadic Cancers
Johann de Bono, Ramesh K Ramanathan, Lida Mina, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 9, 2005
Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group
Graham G Dark, A Hilary Calvert, Robert Grimshaw, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 46) with videos related to
Sort By:
Page
of 5
European Journal of Cancer (Oxford, England : 1990)
|
July 30, 2010
A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit: unplanned admissions as an early indicator of patient attrition
Andre T Brunetto, Joo Ern Ang, David Olmos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 20, 2007
Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers
Ruth Plummer, Gerhardt Attard, Simon Pacey, et al.
The Lancet. Oncology
|
February 2, 2015
Outcomes and endpoints in cancer trials: bridging the divide
Michelle K Wilson, Deborah Collyar, Diana T Chingos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 24, 2011
Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer
Jonathan A Ledermann, Allan Hackshaw, Stan Kaye, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 18, 2008
Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors
Johann S de Bono, Rebecca Kristeleit, Anthony Tolcher, et al.
Cancer
|
October 8, 2016
A study of motivations and expectations of patients seen in phase 1 oncology clinics
Saoirse O Dolly, Eleftheria Kalaitzaki, Martina Puglisi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 12, 2017
Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors
Malaka Ameratunga, Maxime Chénard-Poirier, Irene Moreno Candilejo, et al.
The Journal of Pathology
|
November 21, 2012
Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor
Louise J Barber, Shahneen Sandhu, Lina Chen, et al.
Cancer Discovery
|
March 1, 2017
Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline <i>BRCA1/2</i> Mutations and Selected Sporadic Cancers
Johann de Bono, Ramesh K Ramanathan, Lida Mina, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 9, 2005
Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group
Graham G Dark, A Hilary Calvert, Robert Grimshaw, et al.
Page
of 5